Mill Etienne, MD
Epilepsy · Suffern, NYNPI 1720008907
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 26.1% of the total.
Across 146 payments — averaging $23.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$909
- SK Life Science, Inc.$696
- EMD Serono, Inc.$230
- UCB, Inc.$219
- Acadia Pharmaceuticals Inc$198
- Lilly USA, LLC$154
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,46399%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $909 |
| SK Life Science, Inc. | 9 | $696 |
| EMD Serono, Inc. | 4 | $230 |
| UCB, Inc. | 5 | $219 |
| Acadia Pharmaceuticals Inc | 29 | $198 |
| Lilly USA, LLC | 3 | $154 |
| Neuropace, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $115 |
| Sanofi | 6 | $92 |
| Greenwich Biosciences, Inc. | 4 | $86 |
| Assertio Therapeutics, Inc. | 4 | $81 |
| Avanir Pharmaceuticals, Inc. | 2 | $42 |
| Eisai Inc. | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $40 |
| Amneal Pharmaceuticals LLC | 3 | $39 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| CSL Behring | 2 | $38 |
| Pfizer | 2 | $34 |
| Boston Scientific | 1 | $32 |
| Averitas Pharma Inc. | 1 | $31 |
| Novartis | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Biogen | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $18 |
| Livanova USA, Inc. | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Akcea Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$247
- RNS Neurostimulator Kit$125
- BOTOX$125
- KISUNLA$124
- ZEPOSIA$115
How this compares
$3,489 in reported general payments places this provider in the 60th percentile of 21 epilepsy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 154 | $243,440 |
| Austedo XrDeutetrabenazine | 34 | $205,582 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 17 | $154,469 |
| FycompaPerampanel | 77 | $99,168 |
| EpidiolexCannabidiol (Cbd) | 20 | $65,781 |
| NamzaricMemantine Hcl/Donepezil Hcl | 90 | $61,199 |
| NuplazidPimavanserin Tartrate | 12 | $59,740 |
| UbrelvyUbrogepant | 29 | $47,935 |
| XcopriCenobamate | 42 | $47,472 |
| AptiomEslicarbazepine Acetate | 14 | $45,275 |
| SympazanClobazam | 18 | $41,067 |
| Aimovig AutoinjectorErenumab-Aooe | 49 | $37,077 |
| ValtocoDiazepam | 12 | $33,843 |
| OxycontinOxycodone Hcl | 12 | $33,152 |
| Lamotrigine ErLamotrigine | 73 | $29,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Nayzilam | $219 | $260,101177 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $12 | $205,58234 claims |
| PfizerPanzyga, Nurtec Odt, Dilantin | $34 | $183,97262 claims |
| AbbVieNamzaric, Ubrelvy, Qulipta | $909 | $121,218131 claims |
| Eisai Inc.Fycompa | $40 | $99,16877 claims |
| Acadia Pharmaceuticals IncNuplazid | $198 | $59,74012 claims |
| SK Life Science, Inc.Xcopri | $696 | $47,47242 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $40 | $45,27514 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $13 | $25,05512 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $38 | $8,31411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 21 epilepsy providers in New York.
Other epilepsy in Suffern
- Patricia DuganNew York$97K
- Robert GloverBuffalo$88K
- Daniel FriedmanNew York$66K
- Sheryl HautBronx$61K
- Christopher ElderNew York$41K
- Benjamin BlondStony Brook$40K
- Andres Rodriguez-RuizBrooklyn$9K
- Ping LiBuffalo$6K
- Susanna O'KulaBrooklyn$3K
- Alexus LudwigBuffalo$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.